Federal Rule Extends Telehealth Prescribing for Buprenorphine Up to Six Months—No In-Person Visit Required

On the last day of 2025, the Drug Enforcement Administration and the Department of Health and Human Services issued a rule that fundamentally reshapes how people can access one of the most effective medications for opioid use disorder.

Starting January 1, 2026, healthcare providers can prescribe buprenorphine via telehealth for up to six months without requiring an in-person appointment. The change codifies pandemic-era flexibilities that were set to expire and extends them through the end of 2026—potentially longer if the rule becomes permanent.

For the first time since the Ryan Haight Act of 2008 restricted controlled substance prescribing, a federal regulation explicitly allows buprenorphine treatment to be initiated and maintained entirely through remote care. No initial office visit. No requirement to physically examine the patient before writing the prescription. No geographic barriers forcing people to drive hours to the nearest prescriber.

Just access.

The rule represents one of the most significant expansions of addiction treatment infrastructure in recent memory. Experts say it could save thousands of lives. States say it gives them certainty to invest in telehealth infrastructure. Providers say it removes one of the biggest barriers keeping people from starting treatment when they're ready.

And patients—many of whom discovered telehealth buprenorphine during the pandemic—say it's the reason they're still alive.

What the Rule Actually Does

The December 31 rule builds on temporary flexibilities issued in March 2020, when the COVID-19 pandemic forced federal regulators to suspend normal prescribing restrictions for controlled substances.

Under the Ryan Haight Act, prescribing Schedule III-V controlled substances—which includes buprenorphine—required an in-person medical evaluation. During the pandemic, that requirement was waived. Providers could conduct evaluations by video, audio-only phone calls, or asynchronous messaging. Patients could start buprenorphine the same day they reached out for help.

That flexibility was supposed to be temporary. But as overdose deaths continued climbing—reaching over 107,000 in 2021—public health agencies and researchers began documenting what providers had already observed: telehealth worked. In some cases, it worked better than in-person care.

The new rule makes that flexibility official policy through December 31, 2026. It allows providers to prescribe buprenorphine via telehealth for up to six months without an in-person visit. After six months, patients can continue telehealth care, but must have at least one in-person evaluation. Importantly, the rule also removes recordkeeping requirements for audio-only visits, reducing administrative burden on providers.

Marcelo H. Fernández-Viña, who conducts law and policy analysis at Pew Charitable Trusts' Substance Use Prevention and Treatment Initiative, described the change as "a big deal."

"It makes it easier for people with an opioid use disorder to access treatment," he said in an interview with Route Fifty. "Allowing patients to access addiction treatment remotely has had a huge impact on state efforts to connect people to treatment."

The rule doesn't mandate telehealth. Providers can still require in-person visits if they judge them clinically necessary. But it removes federal barriers that previously made remote prescribing illegal in many circumstances.

Why This Matters Now

Buprenorphine is a partial opioid agonist, meaning it activates opioid receptors in the brain but produces a much weaker effect than full agonists like heroin, fentanyl, or oxycodone. It reduces cravings and withdrawal symptoms without producing euphoria at therapeutic doses.

Decades of research demonstrate that buprenorphine—along with methadone and naltrexone—dramatically reduces overdose mortality, helps people stay in treatment longer, and increases the likelihood of long-term recovery. The medication is so effective that the World Health Organization includes it on its Model List of Essential Medicines.

But for years, access was limited. The Drug Addiction Treatment Act of 2000 required providers to obtain a special waiver—known as an X-waiver—before prescribing buprenorphine for opioid use disorder. Many providers never applied. By 2020, fewer than 7% of U.S. physicians held the waiver.

Congress eliminated the X-waiver requirement in December 2022, allowing any DEA-licensed provider to prescribe buprenorphine. That change opened the door for thousands more practitioners to offer treatment. But geography remained a barrier. Someone living in rural Montana or West Virginia might have to drive hours to reach the nearest prescriber.

Telehealth solves that problem. A patient in a town with no addiction medicine specialists can connect with a provider in another part of the state—or, under certain interstate licensing arrangements, in another state entirely.

The pandemic proved the model could work at scale. Between 2019 and 2021, the number of people receiving buprenorphine via telehealth increased nearly sixfold. Research published by the CDC found that Medicare beneficiaries who received telehealth care for substance use disorder during the pandemic had a 33% lower risk of overdose compared to those who didn't.

Nicole O'Donnell, a certified recovery specialist and director of Penn Medicine's Center for Addiction Medicine and Policy virtual buprenorphine bridge clinic, has seen the impact firsthand.

"The continuation of addiction treatment is crucial, particularly for vulnerable populations," she told Route Fifty. That includes people involved in the criminal justice system, people in rural areas without nearby providers, and people for whom telehealth is a low-cost alternative to in-person care.

O'Donnell also noted that expanding telehealth access helps reduce the strain on emergency departments, which are often the entry point for people in crisis. By making treatment more accessible before a crisis occurs, telehealth can prevent overdoses from happening in the first place—reducing public health costs downstream.

The Data Behind the Policy Shift

When federal regulators suspended in-person requirements in March 2020, researchers immediately began tracking what happened next.

A 2023 study by Pew Charitable Trusts found that patients who started buprenorphine via telehealth were just as likely to stay in treatment as those who started in person. In some demographics—particularly younger patients and those in rural areas—telehealth patients had better retention rates.

Another study, published in JAMA Network Open, found that states with higher rates of telehealth buprenorphine prescribing during the pandemic saw smaller increases in overdose deaths compared to states with lower adoption rates.

The evidence wasn't just about clinical outcomes. It was about access. Patients reported that telehealth eliminated logistical barriers that had previously kept them from seeking treatment: lack of transportation, inflexible work schedules, childcare responsibilities, stigma about being seen entering an addiction clinic.

For people in early recovery, the ability to attend appointments from home meant they didn't have to take time off work or explain their medical situation to employers. For people in active use, it meant they could start treatment the same day they decided they were ready—without waiting weeks for an available in-person appointment.

Timing is critical in addiction medicine. The window when someone is motivated to seek treatment can be narrow. Every barrier—geographic distance, appointment availability, documentation requirements—creates an opportunity for that window to close.

Telehealth removes barriers. The December 31 rule ensures those barriers stay removed.

The Pharmacy Problem That Remains

Even with federal prescribing rules relaxed, one significant obstacle remains: pharmacists sometimes refuse to fill telehealth-based buprenorphine prescriptions.

A 2024 study published in JAMA Internal Medicine found that pharmacists in some regions were skeptical of prescriptions originating from telehealth visits, particularly if the prescriber was located out-of-state or if the patient had no prior prescription history at that pharmacy. Some pharmacists expressed concern about being scrutinized by DEA regulators or state pharmacy boards.

The result: patients who successfully connected with a provider, completed an evaluation, and received a prescription sometimes couldn't actually get the medication.

Fernández-Viña, from Pew, noted that this represents one of the remaining challenges for telehealth buprenorphine expansion. "The federal government has removed a major barrier to treatment access," he said. "But there's still work to do at the state and local levels to ensure patients can actually fill their prescriptions."

Some states have responded by issuing guidance to pharmacists clarifying that telehealth prescriptions are legitimate and should be treated the same as in-person prescriptions. Others have launched educational campaigns aimed at reducing stigma and misinformation about buprenorphine.

The American Pharmacists Association has also issued statements supporting access to medications for opioid use disorder and urging pharmacists to fill legitimate prescriptions without discrimination.

But cultural and regulatory barriers remain. And until those are fully addressed, even the most progressive federal prescribing rules will leave some patients unable to access treatment.

What States Are Doing With This Certainty

One of the most significant effects of the December 31 rule isn't medical—it's fiscal.

State health departments and Medicaid programs have been reluctant to invest heavily in telehealth infrastructure for addiction treatment when federal rules governing that care were subject to annual or quarterly extensions. Every time the DEA issued a temporary extension of pandemic flexibilities, states had to plan around the possibility that those flexibilities might disappear in a few months.

The new rule extends certainty through the end of 2026. That gives states a two-year runway to build systems, train providers, establish reimbursement structures, and expand capacity.

Fernández-Viña described this as a critical shift. "State leaders might feel more confident investing in telehealth services and building them out," he said.

Some states have already moved aggressively to expand telehealth addiction treatment. California's CalRx program, which manufactures and distributes low-cost naloxone statewide, has explored similar models for buprenorphine access. Massachusetts launched a statewide telehealth initiative specifically targeting underserved rural communities.

Other states have used federal grants—including funding from the State Opioid Response program administered by SAMHSA—to build telehealth capacity within community health centers, correctional facilities, and emergency departments.

The December 31 rule doesn't provide new funding. But it provides something equally important: regulatory stability. States can now plan multi-year initiatives knowing the legal framework won't disappear mid-implementation.

The Broader Opioid Treatment Program Update

The December 31 telehealth rule was issued alongside a separate, equally significant policy change: SAMHSA's first update to Opioid Treatment Program (OTP) regulations in 20 years.

OTPs are specialized facilities that provide methadone and buprenorphine treatment, along with counseling and other support services. For decades, federal regulations governing OTPs were among the most restrictive in healthcare, requiring daily in-person visits for methadone dosing and limiting take-home medication allowances.

During the pandemic, those rules were relaxed. Patients with stable recovery could receive multiple weeks' worth of take-home methadone. Telehealth counseling replaced in-person sessions. Admission processes were streamlined.

The new SAMHSA rule makes many of those flexibilities permanent. It allows OTPs to use telehealth for counseling and medical assessments. It expands take-home dosing criteria. It reduces administrative burden for both patients and providers.

Taken together, the DEA/HHS telehealth rule and the SAMHSA OTP update represent the most comprehensive modernization of addiction treatment regulations in a generation.

As one addiction medicine physician put it in a medical journal editorial: "We've finally caught up to where the evidence has been for a decade."

What Comes After December 2026

The current rule extends telehealth prescribing flexibilities through December 31, 2026. What happens after that remains unclear.

Federal agencies could issue another extension. They could make the rule permanent through formal rulemaking. Or they could allow the flexibility to expire, reverting to pre-pandemic restrictions.

Advocacy organizations, medical associations, and patient groups are pushing for permanence. The American Society of Addiction Medicine, the American Medical Association, and dozens of other professional societies have issued statements supporting permanent telehealth access for buprenorphine prescribing.

Public comment periods on earlier versions of the rule drew thousands of responses—the vast majority in favor of maintaining and expanding telehealth flexibilities.

Congress could also act. Bipartisan legislation to codify telehealth prescribing for controlled substances has been introduced in previous sessions, though none has advanced to passage. With opioid overdose deaths declining for the first time in years—down from 107,000 in 2021 to approximately 97,000 in 2023—there's growing political momentum to preserve policies that appear to be working.

But uncertainty remains. And for providers and patients, that uncertainty complicates long-term planning.

O'Donnell, from Penn Medicine, emphasized that her clinic's entire model depends on telehealth access. If federal rules revert to pre-pandemic restrictions, thousands of patients could lose access to care overnight.

"The federal government has removed a major barrier to treatment access," Fernández-Vina said. "Now there's certainty around the future of telehealth. If we take all of that together, telehealth access to buprenorphine can save lives—that's the really big impact we're seeing here."

A Bridge to Treatment, Not a Replacement

It's worth emphasizing what telehealth buprenorphine treatment is—and what it isn't.

It's not a replacement for comprehensive addiction care. The gold standard for opioid use disorder treatment includes medication, counseling, peer support, and case management addressing social determinants of health like housing, employment, and legal issues.

Telehealth makes the medication component more accessible. It doesn't eliminate the need for the other components.

Some patients do well with buprenorphine alone. Others need intensive outpatient programs, residential treatment, or long-term community support. Telehealth is one tool in a much larger toolkit.

But it's an essential tool—particularly for people in the early stages of seeking help, people in areas with limited treatment infrastructure, or people for whom logistical barriers have kept them from accessing care.

Research consistently shows that people who start buprenorphine—through any modality—are more likely to engage with other recovery services over time. The medication stabilizes withdrawal symptoms and cravings, creating space for people to address the underlying issues driving their substance use.

Telehealth removes one of the biggest obstacles to starting that process. And in addiction medicine, starting is often the hardest part.

The Lives Already Saved

Between 2023 and 2024, opioid overdose deaths in the United States fell from approximately 79,000 to 54,000—a 32% decline. It's the largest single-year drop in overdose deaths since the epidemic began.

The decline wasn't driven by one policy or one intervention. It resulted from a combination of factors: expanded naloxone distribution, broader buprenorphine prescribing following elimination of the X-waiver, harm reduction programs, law enforcement efforts targeting illicit fentanyl supply chains, and—yes—telehealth access to treatment.

It's impossible to isolate how many lives were saved specifically by telehealth buprenorphine. But the data strongly suggests it played a role.

Patients who might not have sought treatment because the nearest clinic was 50 miles away could now access care from home. People who couldn't take time off work could attend appointments during lunch breaks. Individuals who felt stigma about being seen at an addiction clinic could receive care privately.

Those aren't hypotheticals. They're real people. And for many of them, telehealth was the difference between seeking treatment and continuing to use.

Nicole O'Donnell sees them every day in her virtual clinic. People who started buprenorphine during the pandemic and are now years into recovery. People who avoided overdose because they could access medication when they needed it, not weeks later after navigating appointment waitlists.

The December 31 rule ensures that those people—and thousands more like them—will continue to have access through at least the end of 2026.

After that, the decision rests with federal regulators and, potentially, Congress.

But for now, the path forward is clear. Telehealth works. The evidence supports it. The policy enables it.

And every day it remains available, more people get the chance to start recovery—and stay alive long enough to see it through.